The raised guidance and strong operating metrics (35% revenue growth, 20% EBITDA margin, record shipments) suggest accelerating commercial momentum. Traders should watch for continued RPO conversion and further reimbursement expansion as catalysts. The stock's historical T+20 performance on bullish calls has been strong (avg +6.91%), supporting a positive near-term bias.
Price Chart
Executive Summary
BrainsWay reported Q2 2026 revenue of $17.1M (+35% YoY), EPS of $0.07 (GAAP), and raised FY 2026 revenue guidance to $68-70M and Adjusted EBITDA guidance to $13-14M. The record system shipments (125 units, +42% YoY) and RPO growth to $80.4M (+30% YoY) signal strong demand momentum, while operating margin expanded to 14% from 5% YoY. The stock is likely to react positively given the beat on consensus estimates ($0.19 vs $0.07 EPS estimate, though GAAP EPS was $0.07) and raised guidance.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $17.1M, +35% YoY from $12.6M
- GAAP EPS $0.07 (basic and diluted), net income $2.7M
- Adjusted EBITDA $3.5M, +141% YoY, margin 20%
- Record 125 Deep TMS systems shipped, +42% YoY
- RPO $80.4M, +30% YoY
- Raised FY 2026 revenue guidance to $68-70M (from $66-68M)
- Raised FY 2026 Adjusted EBITDA guidance to $13-14M (from $12-14M)
- Operating cash flow $6.3M in Q2 2026
- Cash and equivalents $62.1M as of June 30, 2026
Financial Impact
Revenue beat consensus by $0.6M ($17.1M vs $16.5M est); GAAP EPS $0.07 vs $0.07 consensus (in-line); raised FY guidance implies ~30-34% revenue growth and ~90-100% EBITDA growth YoY
Risk Factors
- Guidance assumes continued reimbursement expansion and utilization growth, which may not materialize if payer coverage slows
- Competition from other TMS and neurostimulation modalities could pressure market share
- Dependence on FDA-cleared indications (MDD, OCD, smoking addiction) limits addressable market without new approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343549 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 6-K | $14.16 $13.63 | ▼ −3.74% | ▼ −3.08% | $12.71 (−10.24%) |
Aug 27, 2026 5w ago | 6-K | $14.40 $14.51 | ▲ +0.76% | ▲ +0.50% | $12.71 (−11.74%) |
Aug 12, 2026 7w ago | 6-K | $16.47 $14.97 | ▼ −9.11% | ▼ −7.14% | $12.71 (−22.83%) |
Aug 12, 2026 7w ago | 6-K | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Aug 12, 2026 7w ago | Press Release | $16.60 $15.17 | ▼ −8.61% | ▼ −8.17% | $12.71 (−23.43%) |
Jul 20, 2026 10w ago | 6-K | $16.50 $15.97 | ▼ −3.21% | ▼ −2.79% | $12.71 (−22.97%) |
Jul 16, 2026 11w ago | 6-K | $14.84 $16.51 | ▲ +11.25% | ▲ +12.92% | $12.71 (−14.35%) |
Jun 29, 2026 13w ago | Press Release | $15.17 $16.02 | ▲ +5.60% | ▲ +4.22% | $12.71 (−16.22%) |
Jun 22, 2026 14w ago | 6-K | $14.38 $15.17 | ▲ +5.49% | ▲ +5.95% | $12.71 (−11.61%) |
May 18, 2026 19w ago | Press Release | $14.88 $15.89 | ▲ +6.79% | ▲ +5.17% | $12.71 (−14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access